"B-Cell Activating Factor" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A tumor necrosis factor superfamily member that plays a role in the regulation of B-LYMPHOCYTE survival. It occurs as a membrane-bound protein that is cleaved to release an biologically active soluble form with specificity to TRANSMEMBRANE ACTIVATOR AND CAML INTERACTOR PROTEIN; B-CELL ACTIVATION FACTOR RECEPTOR; and B-CELL MATURATION ANTIGEN.
|B-Cell Activating Factor
- B-Cell Activating Factor
- Activating Factor, B-Cell
- B-Lymphocyte Activating Factor
- Activating Factor, B-Lymphocyte
- B Lymphocyte Activating Factor
- THANK Protein
- BAFF Ligand
- BLyS Protein
- B Cell Activating Factor
- B Lymphocyte Stimulator
- CD257 Antigen
- Antigen, CD257
- Antigens, CD257
- TNF and APOL-Related Leukocyte Expressed Ligand 1
- TNF and APOL Related Leukocyte Expressed Ligand 1
- TNF Superfamily, Member 13b
- Tumor Necrosis Factor Ligand Superfamily Member 13b
- CD257 Antigens
- TNFSF13B Protein
- TALL-1 Protein
- TALL 1 Protein
Below are MeSH descriptors whose meaning is more general than "B-Cell Activating Factor".
Below are MeSH descriptors whose meaning is more specific than "B-Cell Activating Factor".
This graph shows the total number of publications written about "B-Cell Activating Factor" by people in this website by year, and whether "B-Cell Activating Factor" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
|Year||Major Topic||Minor Topic||Total|
To return to the timeline, click here.
Below are the most recent publications written about "B-Cell Activating Factor" by people in Profiles.
Impact of Belimumab on Organ Damage in Systemic Lupus Erythematosus. Arthritis Care Res (Hoboken). 2022 Nov; 74(11):1822-1828.
Associations Between Smoking and Systemic Lupus Erythematosus-Related Cytokines and Chemokines Among US Female Nurses. Arthritis Care Res (Hoboken). 2021 11; 73(11):1583-1589.
CNS Autoimmune Responses in BCMA-Deficient Mice Provide Insight for the Failure of Atacicept in MS. Neurol Neuroimmunol Neuroinflamm. 2021 05; 8(3).
Unique Sjögren's syndrome patient subsets defined by molecular features. Rheumatology (Oxford). 2020 04 01; 59(4):860-868.
Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2018 06; 77(6):883-889.
Efficacy and Safety of Atacicept in Patients With Systemic Lupus Erythematosus: Results of a Twenty-Four-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm, Phase IIb Study. Arthritis Rheumatol. 2018 02; 70(2):266-276.
Clinical trial parameters that influence outcomes in lupus trials that use the systemic lupus erythematosus responder index. Rheumatology (Oxford). 2018 01 01; 57(1):125-133.
Clinical and Serologic Features in Patients With Incomplete Lupus Classification Versus Systemic Lupus Erythematosus Patients and Controls. Arthritis Care Res (Hoboken). 2017 12; 69(12):1780-1788.
The Biomarkers of Lupus Disease Study: A Bold Approach May Mitigate Interference of Background Immunosuppressants in Clinical Trials. Arthritis Rheumatol. 2017 06; 69(6):1257-1266.
Gene Expression and Pharmacodynamic Changes in 1,760 Systemic Lupus Erythematosus Patients From Two Phase III Trials of BAFF Blockade With Tabalumab. Arthritis Rheumatol. 2017 03; 69(3):643-654.